Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.59 |
| ▸ | F10 | P00742 | 14/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066505 | 0.88 | HDAC8 (0.56) | MRGPRX4F10NR4A2NR4A1NR4A3 | |
| SCHEMBL5093819 | 0.86 | F10 (0.62) | F10TTR | |
| SCHEMBL6066457 | 0.85 | F10 (0.60) | MRGPRX4F10NR4A2TTR | |
| SCHEMBL6066520 | 0.85 | F10 (0.54) | MRGPRX4F10NR4A2NR4A1NR4A3 | |
| SCHEMBL6066547 | 0.84 | F10 (0.56) | MRGPRX4F10NR4A2NR4A1NR4A3 | |
| SCHEMBL6066364 | 0.84 | F10 (0.56) | MRGPRX4F10NR4A2NR4A1NR4A3 | |
| SCHEMBL6066583 | 0.84 | F10 (0.56) | MRGPRX4F10NR4A2NR4A1NR4A3 | |
| SCHEMBL6066449 | 0.83 | F10 (0.56) | MRGPRX4F10NR4A2TTR | |
| SCHEMBL6066368 | 0.83 | F10 (0.55) | MRGPRX4F10NR4A2NR4A1NR4A3 | |
| SCHEMBL6066448 | 0.82 | F10 (0.56) | MRGPRX4F10NR4A2NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435747-B2 | Guanidine and amidine derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-14 | — | — | US | disclosed |
| EP-1345900-B1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-17 | — | — | EP | disclosed |
| US-7067665-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-27 | — | — | US | disclosed |
| US-6953857-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or viia | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| US-20050143419-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-30 | — | — | US | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| EP-1345900-A1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| US-20020173656-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1217000-A1 | Inhibitors of factor Xa and factor VIIa | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002046159-A1 | GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173656-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | F5, F9, F10 | MRGPRX4 679/4885F10 3/4885NR4A2 4782/4885 |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | MRGPRX4 2115/4885F10 7/4885NR4A2 4257/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | MRGPRX4 466/4885F10 8/4885NR4A2 3567/4885 |
| US-20050143419-A1 | Guanidine and amidine derivatives as factor Xa inhibitors | F5, F10, F12 | MRGPRX4 844/4885F10 2/4885NR4A2 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.